Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms
Clin. transl. oncol. (Print)
; 20(5): 561-569, mayo 2018. ilus, tab
Artigo
em Inglês
| IBECS
| ID: ibc-173531
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Neuroendocrine neoplasms (NENs) are considered a heterogeneous and rare entity. Its natural history is influenced by multiple clinicopathological characteristics, which guide the management of these patients. The development of molecular biology reveals that the PI3K-AKT-mTOR pathway plays a relevant role in tumorigenesis and progression of NENs. Mammalian target of rapamycin (mTOR) inhibitors, targeted agents that block this pathway, has improved outcomes in neuroendocrine tumors (NETs). Different therapeutic approaches, such as somatostatin analogs, chemotherapy, peptide receptor radionuclide therapy, and targeted agents, have shown benefits in the treatment of NETs. However, there are not any established prognostic or predictive biomarkers to select the best therapy option to individualize treatment. Although a relation between alterations in the PI3K-AKT-mTOR pathway and clinical outcomes has not been found, these anomalies are considered attractive biomarkers. Additional molecular analysis should be integrated in future clinical trials' design to identify potential predictive or prognostic biomarkers
RESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Tumores Neuroendócrinos
/
Proteínas Proto-Oncogênicas c-akt
/
Fosfatidilinositol 3-Quinase
/
Terapia de Alvo Molecular
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2018
Tipo de documento:
Artigo
Instituição/País de afiliação:
University Hospital Ramon y Cajal/Spain